Sanara is a surgical and wound-care medtech company that has been narrowing its strategy toward surgical products after moving its Tissue Health Plus operations into discontinued operations; the MiMedx deal is intended to give that portfolio more commercial scale.
The shareholder hurdle is cleared, but this was largely expected. Sanara shareholders provided enough support for the merger proposal, and the adjournment proposal was not needed: “Proposal No. 3 was not submitted to Sanara’s shareholders for approval at the Special Meeting because there were sufficient votes to approve Proposal No. 1.” 〔0〕 The 69.78% quorum shows broad participation, but the supplied filing excerpt does not include the exact for, against, and abstain totals. 〔1〕
The remaining issue is regulatory timing, not shareholder support. MiMedx withdrew and refiled its Hart-Scott-Rodino notification to give the Federal Trade Commission more review time, moving the stated waiting-period expiration to October 15, 2026. 〔2〕 That is a modest complication versus the original timetable, although the merger was already announced and the parties had previously disclosed an expected closing by year-end 2026.
The deal still advances Sanara’s strategic transition. The proposed combination would fold Sanara’s surgical portfolio into MiMedx, with the transaction announced at approximately $350 million of enterprise value and designed to create a larger combined surgical platform. The vote removes the company-controlled obstacle; antitrust clearance and the other merger conditions remain.
Bottom line: This filing advances the merger story by removing the shareholder-approval risk, but it does not complete the transaction. The key near-term uncertainty is now the extended FTC review, with October 15, 2026 as the stated waiting-period date.
Read the original 8-K on SEC EDGAR ↗